Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

09. April 2026 07:00 ET | Quelle: Nkarta, Inc.

Nkarta to Participate in Needham Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
09. April 2026 07:00 ET | Quelle: Rani Therapeutics, LLC

Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
09. April 2026 07:00 ET | Quelle: Foghorn Therapeutics, Inc.

Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

New preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities in combination with an anti-PD-1 antibody in SMARCA4 (BRG1)-mutant lung cancer Preclinical...
09. April 2026 06:05 ET | Quelle: Research and Markets

$1.05 Bn Biopharmaceutical CXO Markets - Global Forecast Report 2026-2032: How Leading Pharmas Such as Pfizer, Roche, Novartis, Sanofi, and AstraZeneca Navigate the Evolving Dynamics

Dublin, April 09, 2026 (GLOBE NEWSWIRE) -- The "Biopharmaceutical CXO Market - Global Forecast 2026-2032" report has been added to ResearchAndMarkets.com's offering. The Biopharmaceutical CXO...
09. April 2026 06:00 ET | Quelle: Zymeworks Inc.

Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth

• Adam Schayowitz, Ph.D., MBA appointed as Head of R&D• Scott Platshon appointed as Chief Business Officer VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc....
09. April 2026 04:44 ET | Quelle: Research and Markets

Biopharmaceutical CMO & CRO (Analytical, Cell Culture, Clinical Development, Fill-Finish, Formulation, Preclinical Development, Process Development) Market Research & Global Forecast Report 2026-2032

Dublin, April 09, 2026 (GLOBE NEWSWIRE) -- The "Biopharmaceutical CMO & CRO Market - Global Forecast 2026-2032" report has been added to ResearchAndMarkets.com's offering. The...
09. April 2026 04:34 ET | Quelle: LEADS BIOLABS CO., LTD.

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results

Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) announced that its proprietary PD-L1/4-1BB bispecific antibody,
09. April 2026 04:03 ET | Quelle: Research and Markets

Artificial Intelligence in Pharmaceutical Market Research and Global Forecast Report 2026-2032

Dublin, April 09, 2026 (GLOBE NEWSWIRE) -- The "Artificial Intelligence in Pharmaceutical Market - Global Forecast 2026-2032" report has been added to ResearchAndMarkets.com's offering. The...
09. April 2026 04:00 ET | Quelle: BDC

BDC launches a $150‑million Life Sciences Venture Fund

MONTREAL, April 09, 2026 (GLOBE NEWSWIRE) -- The Business Development Bank of Canada (BDC) today announced the launch of its $150‑million Life Sciences Venture Fund, created to support the next...
09. April 2026 02:00 ET | Quelle: Trogenix

Trogenix announces publication of breakthrough pre-clinical data in Nature demonstrating complete tumour eradication and durable protection in aggressive brain cancer model

A single-dose of Trogenix’s proprietary Synthetic Super-Enhancers achieved complete tumour elimination in 83% of treated cases with no toxicity over 11 months and no tumour recurrence in a brain...

Vorherige Seite

Nächste Seite